<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> is known to lower the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality </plain></SENT>
<SENT sid="1" pm="."><plain>However, the effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> in <z:e sem="disease" ids="C0677950" disease_type="Neoplastic Process" abbrv="">stage IV colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients with <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (DM) remains unknown </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to evaluate the effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response and survival in stage IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with DM </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We identified 106 patients who were diagnosed with both stage IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and DM (81 patients who underwent palliative chemotherapy and 25 patients who underwent curative resection) </plain></SENT>
<SENT sid="4" pm="."><plain>Retrospective data of each patient's clinical characteristics, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response, and survival rate were compared between two groups of patients who either were or were not administered <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: For the palliative chemotherapy group, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response, change in target lesion size, progression free survival rate, and overall survival rate were not significantly different between the <z:chebi fb="0" ids="6801">metformin</z:chebi> group and the non-<z:chebi fb="0" ids="6801">metformin</z:chebi> group on univariate and multivariate analysis </plain></SENT>
<SENT sid="6" pm="."><plain>For the curative resection patient group, <z:chebi fb="0" ids="6801">metformin</z:chebi> use was associated with increased disease free survival on univariate analysis (p=0.012) and multivariate analysis (hazard ratio, 0.024; 95% CI 0.001-0.435; p=0.010), but not with overall survival </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> use in stage IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with <z:mp ids='MP_0002055'>diabetes</z:mp> was shown to be associated with a lower risk of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence after curative resection </plain></SENT>
</text></document>